HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial

Overview of attention for article published in Clinical Cancer Research, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 23 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 33 X posts from 23 X users, with an upper bound of 36,867 followers.

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial https://t.co/JBrc7ee3Na #ScientiaVH

25 Apr 2023

Reply Repost Favourite

RT @CCR_AACR: Post hoc translational biomarker study of the Phase 3 JACOB trial (HER2-positive metastatic or unresectable gastric cancer).…

16 Feb 2023

Reply Repost Favourite

Post hoc translational biomarker study of the Phase 3 JACOB trial (HER2-positive metastatic or unresectable gastric cancer). https://t.co/2vmYdISVxh https://t.co/3YdBWUXN5Q

16 Feb 2023

Reply Repost Favourite

RT @ArndtVogel: 🔥HER2 CNV in HER2+ #GastricCancer receiving Trastuzumab/Pertuzumab/CTx @CCR_AACR https://t.co/6CazqZsFms ✅post-hoc JACOB ph…

16 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 29 additional X posts.